Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

14th Annual World ADC London 2024 – Presentation

Events, News, Presentations

14th Annual World ADC London 2024 – Presentation...

mAbs Journal – Production of Antibodies and Antibody Fragments Containing Non-Natural Amino acids in Escherichia Coli

News, Presentations

mAbs Journal – Production of Antibodies and Antibody Fragments Containing Non-Natural Amino acids in Escherichia Coli View...

Sutro Biopharma to Participate in Upcoming Investor Conferences

Events, News, Presentations, Press Releases

Sutro Biopharma to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., February 6, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug...

Luvelta Forum – Presentation

Events, News, Press Releases

Luvelta Forum – Presentation...

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Events, News, Press Releases

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant...

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Events, News, Presentations, Press Releases

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024 SOUTH SAN FRANCISCO, Calif., December 14, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a...
« Older Entries
Next Entries »

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.